Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
Consultation ARM 62 sought your views on the reclassification from Pharmacy (P) to General Sales List (GSL) of Lamisil Once 1% Cutaneous Solution for the treatment of tinea pedis (athlete's foot). A total of 12 responses to the consultation were received, of which six were in favour, five did not agree with the proposal and one had no comment.
Copies of the responses (excluding those marked as 'in confidence') are available below.
| Professional pharmaceutical societies, individual pharmacists and other pharmaceutical bodies |
|---|
|
No to reclassification
|
|
No comment |
| Medical profession and royal colleges |
|---|
|
Yes to reclassification |
| Others |
|---|
|
Yes to proposal |
